2025
95 Assessing genetic diversity of the Pfs25 vaccine candidate: Implications for malaria transmission-blocking vaccine in Africa
Orfano A, Cisse A, Sheng Z, Guo Y, Han L, Thiam L, Mangou K, Moore A, Ba A, Li R, Pouye M, Diallo F, Sene S, Ngom E, Sadio B, Mbengue A, Membi C, Bazié T, Somé F, Olson N, Patel S, Shapiro L, Parikh S, Foy B, Cappello M, Premji Z, Dabiré R, Ouedraogo J, Bei A. 95 Assessing genetic diversity of the Pfs25 vaccine candidate: Implications for malaria transmission-blocking vaccine in Africa. Journal Of Clinical And Translational Science 2025, 9: 29-29. PMCID: PMC12050472, DOI: 10.1017/cts.2024.767.Peer-Reviewed Original ResearchSingle nucleotide polymorphismsTransmission-blocking vaccinesGenetic diversityComplex infectionSymptomatic P. falciparum infectionsMalaria transmission-blocking vaccineVaccine candidatesVariant frequenciesNovel single nucleotide polymorphismsNonsynonymous single nucleotide polymorphismsRare variantsFrequency of single nucleotide polymorphismsP. falciparum 3D7Plasmodium falciparum samplesAmplicon deep sequencingMalaria eliminationCountry-specific prevalenceEndemic African countriesPfs25 proteinGeneious softwareParasite genetic diversityProportion of mutant allelesAmplicon sequencingPfs25Mutant alleles
2022
Evaluation of the Pfs25-IMX313/Matrix-M malaria transmission-blocking candidate vaccine in endemic settings
Mulamba C, Williams C, Kreppel K, Ouedraogo J, Olotu A. Evaluation of the Pfs25-IMX313/Matrix-M malaria transmission-blocking candidate vaccine in endemic settings. Malaria Journal 2022, 21: 159. PMID: 35655174, PMCID: PMC9161629, DOI: 10.1186/s12936-022-04173-y.Peer-Reviewed Original ResearchConceptsEndemic settingsMalaria transmission-blocking vaccineHuman vaccine trialsTransmission-blocking vaccinesPublic health importanceMosquito vectorsMiddle-income settingsAnti-malarial drugsImmunological mechanismsCandidate vaccinesVaccine trialsHealthy individualsIncome settingsTransmission blockingHealth importanceMalaria controlMalaria parasitesVaccineLocal interventionsDrugsInterventionSettingSexual stagesPfs25Disease
2013
Anti-Pfs25 Human Plasma Reduces Transmission of Plasmodium falciparum Isolates That Have Diverse Genetic Backgrounds
Da D, Dixit S, Sattabonkot J, Mu J, Abate L, Ramineni B, Ouedraogo J, MacDonald N, Fay M, Su X, Cohuet A, Wu Y. Anti-Pfs25 Human Plasma Reduces Transmission of Plasmodium falciparum Isolates That Have Diverse Genetic Backgrounds. Infection And Immunity 2013, 81: 1984-1989. PMID: 23509152, PMCID: PMC3676035, DOI: 10.1128/iai.00016-13.Peer-Reviewed Original ResearchConceptsPhase 1 trialParasite isolatesMalaria transmission-blocking vaccineTransmission-reducing activityTransmission-blocking activityPlasmodium falciparum isolatesTransmission-blocking vaccinesPlasmodium falciparum parasitesLimited sequence polymorphismPfs25 antibodiesMontanide ISA51Immune plasmaNonimmune controlsRecombinant Pfs25Falciparum isolatesPfs25 geneFalciparum parasitesGenetic backgroundPatientsBurkina FasoPfs25VaccineTrialsNucleotide polymorphismsIsolates
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply